Cellcept and Myfortic Linked to Birth Defects

FDA is advising healthcare professionals about an increased risk of fetal harm when women become pregnant while being treated with the immunosuppressant drugs Cellcept (mycophenolate mofetil) or Myfortic (mycophenolic acid). Myfortic is approved to prevent kidney transplant rejection. CellCept is … Continue reading →